Approval · Notice of Compliance 4047 · 1997
RETAVASE: Notice of Compliance 4047
Issued August 29, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4047
- Date
- August 29, 1997
- Company
- Boehringer Mannheim (Canada) LteeLaval, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Thrombolytic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RETAVASE | 02233013 | Cancelled Post Market |
Medicinal ingredients
- RETEPLASE 10.8 UNIT per VIAL